New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement (2018)
- Authors:
- USP affiliated authors: FARIAS, KELEN CRISTINA RIBEIRO MALMEGRIM DE - FCFRP ; RODRIGUES, MARIA CAROLINA DE OLIVEIRA - FMRP ; COURI, CARLOS EDUARDO BARRA - FMRP
- Unidades: FCFRP; FMRP
- DOI: 10.3389/fimmu.2018.01086
- Subjects: AUTOIMUNIDADE; CÉLULAS VEGETAIS; TRANSPLANTE DE ÓRGÃOS; BIOMARCADORES; DIABETES MELLITUS; TRANSPLANTE AUTÓLOGO; IMUNOSSUPRESSÃO
- Keywords: Type 1 diabetes; Immunotherapy; Autologous hematopoietic stem cell transplantation; Immunologic reset; Autoimmunity; Beta cell preservation
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Frontiers in Immunology
- ISSN: 1664-3224
- Volume/Número/Paginação/Ano: v. 9, art. 1086, 2018
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
COURI, Carlos E. B. e FARIAS, Kelen Cristina Ribeiro Malmegrim de e OLIVEIRA, Maria Carolina. New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement. Frontiers in Immunology, v. 9, 2018Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2018.01086. Acesso em: 25 abr. 2024. -
APA
Couri, C. E. B., Farias, K. C. R. M. de, & Oliveira, M. C. (2018). New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement. Frontiers in Immunology, 9. doi:10.3389/fimmu.2018.01086 -
NLM
Couri CEB, Farias KCRM de, Oliveira MC. New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement [Internet]. Frontiers in Immunology. 2018 ; 9[citado 2024 abr. 25 ] Available from: https://doi.org/10.3389/fimmu.2018.01086 -
Vancouver
Couri CEB, Farias KCRM de, Oliveira MC. New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement [Internet]. Frontiers in Immunology. 2018 ; 9[citado 2024 abr. 25 ] Available from: https://doi.org/10.3389/fimmu.2018.01086 - Editorial: immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand?
- Teplizumab in relatives at risk for type 1 diabetes. [Carta]
- Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II
- Lower Insulin-Dose Adjusted A1c (IDAA1c) is associated with less complications in individuals with type 1 diabetes treated with hematopoetic stem-cell transplantation and conventional therapy
- Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: where do we stand?
- Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand?
- Diabetes mellitus tipo 2 e doença aterosclerótica
- CMV-specific clones may lead to reduced TCR diversity and relapse in systemic sclerosis patients treated with AHSCT [Carta]
- Autologous hematopoietic stem cell transplantation for autoimmune diseases: from mechanistic insights to biomarkers
- Transplante de células-tronco hematopoéticas para doenças auto-imunes graves e refratárias ao tratamento convencional
Informações sobre o DOI: 10.3389/fimmu.2018.01086 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
